CODE formulas have gone through extensive evaluation, and many have undergone clinical studies. CODE Health has partnered with Beech Tree Labs and holds licensing to molecular formulas invented by Dr. John McMichael. CODE Health obtained these formulas to develop over-the-counter products safe for people and animals.
For those seriously interested in the scientific details of our products, please feel free to request the lengthy research that was conducted and required in order to obtain patents.
The following are just a few of the research articles that have been published.
Mathews, M., Bernstein, R. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 304, 177–179 (1983). https://doi.org/10.1038/304177a0
Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol. 1990 Sep;81(3):373-9. doi: 10.1111/j.1365-2249.1990.tb05341.x. PMID: 2168821; PMCID: PMC1534997.
Stephen Mamber, John McMichael, 2006. Microdose DNA for the Treatment of Acute and Chronic Respiratory Diseases and Otitis Media. The Journal of the American Nutraceutical Association, Vol. 9, No. 1, 13-22. https://beechtreelabs.com/wpcontent/uploads/2022/07/Microdose_DNA_for_the_treatment.pdfMcMichael.
Visit clinicaltrials.gov, the U.S. National Library of Medicine database of clinical studies conducted around the world. ClinicalTrials.gov identifier (NCT number): NCT04522830
Mamber SW, Hatch T, Miller CS, et al., 2022. Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis of Evidence-based Integrative Medicine. Jan-Dec; 27:2515690X221078004. DOI: 10.1177/2515690×221078004. PMID: 35142535; PMCID: PMC8841908.
Stephen W Mamber, Steven Krakowka, Jeffrey Osborn, Lloyd Saberski, Ryan G Rhodes, Albert E Dahlberg, Sunthorn Pond-Tor, Kara Fitzgerald, Neal Wright, Sarah Beseme, John McMichael, 2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity? May 13; 5(3):e00288-20. doi: 10.1128/mSphere.00288-2
Sue C. Killian, MS, with John McMichael, PhD. Indianapolis: Xlibris, 2017. Allergy and Cross-Reactivity. (book).
Sue Killian and John McMichael.2015. Allergy Induced Back Pain: A Report of Two Cases of Allergy Disorders and Therapy, Vol. 2, Issue 1, 1-4.
John E. McGeary, Volkan Gurel, Valerie S. Knopik, JamesSpaulding, JohnMcMichael, 2011. Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain. Neuropeptides, 45(5): 317-22. doi:10.1016/j.npep.2011.06.002
David H. Overstreet, Kellie Fredericks, Darin Knapp, George Breese, John McMichael, 2010. Nerve growth factor (NGF) has novel antidepressant-like properties in rats. Pharmacol Biochem Behav. Feb; 94(4): 553–560. doi: 10.1016/j.pbb.2009.11.010
Bonnie Rush Moor, Steven Krakowka, Joseph M. Cummins, James T. Robertson, Changes in airway inflammatory cell populations in Standardbred racehorses after interferon-alpha administration. Veterinary Immunology and Immunopathology, Volume 49, Issue 4, 1996, Pages 347-358, ISSN 0165-2427, https://doi.org/10.1016/0165-2427(95)05480-4. (https://www.sciencedirect.com/science/article/pii/0165242795054804)
Weiss, R & Cummins, Joseph & Richards, Alan. (1991). Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. Journal of the American Veterinary Medical Association. 199. 1477-81.
Bennett, Alayne & Smith, David & Cummins, Martin & Jacoby, Peter & Cummins, Joseph & Beilharz, Manfred. (2013). Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: A double-blind, parallel controlled trial during an influenza pandemic year. Influenza and other respiratory viruses. 7. 10.1111/irv.12094.